The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 68.50
Bid: 65.00
Ask: 72.00
Change: 6.00 (9.60%)
Spread: 7.00 (10.769%)
Open: 62.50
High: 68.50
Low: 62.50
Prev. Close: 62.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bleepa rolled out at PAH NHS Trust for Covid-19

20 Apr 2020 07:00

RNS Number : 1183K
Feedback PLC
20 April 2020
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR").

 

Feedback plc

 

Bleepa® rolled-out across Pennine Acute Hospitals NHS Trust to help manage the COVID-19 peak

 

● Pennine Acute Hospitals NHS Trust rolls-out Bleepa® the secure medical imaging based communication platform to help manage the COVID-19 workflow

● Team to team referrals of COVID-19 cases to be managed through Bleepa® to ensure rapid clinical assessment

Bleepa® to support COVID-19 clinical research study, the Recovery Trial

 

London, 20 April 2020: Feedback Medical Ltd, a wholly-owned subsidiary of Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that Bleepa®, Feedback's flagship imaging-based communication platform, will be rolled-out across the Pennine Acute Hospitals NHS Trust with immediate effect as a key patient management tool to assist its coronavirus response.

 

As the NHS meets the challenge of COVID-19, critical medical imaging studies are increasingly vital, with chest X-rays and CT scans being key aids. As a pioneering Trust and GDE Fast Follower site, Pennine Acute Hospitals NHS Trust has looked at innovative digital solutions to support greater collaboration and communication amongst clinical staff on the front-line and have recognised Bleepa® as being a key asset in their response to this outbreak.

 

The Trust is already familiar with the Bleepa® technology having piloted the technology for many months within the Respiratory inpatient referral pathway. The feedback from the pilot has been used to hone the tool and enable an improved version of Bleepa® to have been developed which is now being deployed to assist the Trust in delivering its COVID-19 response.

 

New features were developed at pace within a two week period by the Feedback team, and their development partners Future Processing and include a smart form for clinical data entry, group transfer and the ability to designate patients with a clinical status such as ventilation status. These features enable Coronavirus cases to be tracked as they move through the clinical pathways and more easily enable team to team referral.

 

Around 200 frontline clinicians within the Acute Medical Team have now been enrolled on Bleepa® with more anticipated in the coming week.

 

The unique features of the app will facilitate key decision processes within the Trust's COVID-19 workflow by connecting clinical decision makers with frontline personnel and making relevant imaging available at the push of a button. Bleepa® will capture the clinical dialogue and decision making processes, subsequently forming part of the patient record after the admission is completed.

 

In addition to supporting clinical delivery Bleepa® will facilitate a clinical research trial being run by the Trust. The Recovery Trial is being conducted by a dedicated team of Research Nurses within the Trust and will seek to assess the recovery pathway of different patient groups from COVID-19.

 

Tom Oakley, CEO of Feedback plc, said:

 

"Pennine have been instrumental in the development and evolution of Bleepa® and it is very rewarding to now put what we have developed to use in assisting the Trust at a time of great need. It will become increasingly important for clinicians to have timely access to medical imaging and other team members especially in light of a growing requirement for remote access due to self isolation. Bleepa® is the only imaging communication tool that can deliver the required workflow support at the scale required and it's not just Radiologists who need access to imaging now but all frontline personnel. The whole Company feels deeply privileged to be able to help and we are immensely proud to see our tool deployed and already making a difference to delivery at this time. We will work hard to ensure that Bleepa® can support and protect as many frontline NHS staff as possible and we are already looking to support other NHS Trusts who would similarly benefit from our system."

 

 

Georges Ng Man Kwong, Consultant Chest Physician (Oldham Care Organisation) and CCIO (Pennine Acute NHS Trust, part of Northern Care Alliance), said:

 

"After an initial pre-Covid pilot study Bleepa® was identified as a potential secure solution to register and identify patients suitable for the RECOVERY trial ( a national randomised study looking at novel Covid treatments) and as a messaging application to support (multi-speciality) clinical decision making. It has rapidly been adopted by our research nurses and clinician specialists in key acute areas across the hospital providing additional opportunities to identify and track patients receiving respiratory and palliative care respectively. The extraordinary circumstances within the NHS during the Coronavirus pandemic has enabled us to test and modify the Bleepa® solution at pace and go-live within only a few weeks with satisfactory clinical and technical specifications. Our on-going engagement with Bleepa® continues to identify additional specialties and scope to widen its' application within our health-care organisation that will aid clinicians both during this challenging period and once the pandemic crisis has ended."

 

 

Bleepa® is a secure image-based communication platform which provides access to clinical grade medical images and facilitates instant messaging based case discussion through a zero footprint application. Bleepa® can be accessed from any internet connected device including phones, tablets, laptops and desktops; clinicians can use their own devices and therefore no additional hardware is required.

 

Any medical imaging investigation can be seamlessly shared through Bleepa® to the entire clinical team, even if those teams are geographically separated or having to work remotely. Cases can be discussed through secure instant messaging and image annotation, allowing comments and decisions to be communicated instantly between team members. Importantly, during the outbreak, Bleepa® can enable case review by clinicians at other hospitals where multisite communication is needed.

 

Home-based image review and case discussion at this scale requires a new infrastructure and a secure bespoke imaging solution which is capable of scaling to meet these demands. Bleepa® is designed for exactly this purpose and overcomes the problems associated with trying to scale traditional VPN-based remote access solutions to hospital software.

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

IR@fbk.com

 

 

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656

 

 

Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey

+44 (0)20 7469 0936

 

 

Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 (0)20 3815 8880

 

 

Instinctif Partners

Melanie Toyne-Sewell / Phillip Marriage

+44 (0)20 7457 2020

+44 (0)7890 022 814

feedbackplc@instinctif.com

 

 

Notes to editors

 

About Feedback plc - www.fbk.com

 

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer.

 

Feedback has launched Bleepa, a new secure, encrypted medical communication app for clinicians accessible through smartphones, tablets and desktops that facilitates rapid clinical messaging and review of medical grade imaging for all members of a clinical team, directly from a hospital Picture Archiving and Communications System (PACS). For more information on Bleepa, see www.bleepa.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCILMBTMTTBTFM
Date   Source Headline
30th Jun 20172:21 pmRNSHolding(s) in Company
30th Jun 201712:41 pmRNSIssue of Equity
8th Jun 20171:15 pmRNSCCI Exclusive Distributor Agreement with Korea ISG
8th Jun 20171:11 pmRNSDirectorate Change
1st Jun 20179:23 amRNSTotal Voting Rights
30th May 20174:38 pmRNSFurther re. Notice of Resignation of Director
18th May 20177:00 amRNSProgress with CE Mark and trading update
12th May 201711:57 amRNSHolding(s) in Company
2nd May 20177:00 amRNSNotice of Resignation of Director
26th Apr 20177:00 amRNSIssue of Equity
30th Mar 20177:00 amRNSLetter of Intent signed and trading update
3rd Mar 20177:00 amRNSAppointment of Joint Broker
20th Feb 20177:00 amRNSHalf-year Report
23rd Jan 20171:28 pmRNSRe: Media Articles
30th Nov 20165:00 pmRNSTotal Voting Rights
24th Nov 201612:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20161:20 pmRNSIssue of Equity & Director / PDMR Shareholding
23rd Nov 201610:33 amRNSResult of AGM
16th Nov 20167:00 amRNSAttendance at RSNA 2016
19th Oct 20163:17 pmRNSRe: Directorate
19th Oct 20167:00 amRNSFinal results for the year ended 31 May 2016
21st Sep 201612:30 pmRNSTrading Update
28th Jul 20161:31 pmRNSCollaboration with Future Processing
1st Jun 201612:30 pmRNSAppointment of Non-Executive Chairman
3rd May 201612:00 pmRNSDisposal
2nd Mar 20167:00 amRNSChange of Nominated Adviser
22nd Feb 20167:00 amRNSInterim Results for the 6 months ended 30 Nov 2015
30th Nov 20152:59 pmRNSResult of AGM
23rd Nov 20157:00 amRNSTexRAD Update
6th Nov 20157:01 amRNSDirectorate Change
6th Nov 20157:00 amRNSFinal Results
8th Oct 20157:00 amRNSStrategy Update
6th Oct 20159:45 amRNSNHS publication on potential application of TexRAD
5th Oct 20157:00 amRNSTexRAD Prostate Cancer Product Development
28th Sep 20157:00 amRNSLicence of TexRAD to Stone Checker
9th Sep 20157:00 amRNSFirst sale of TexRAD in China
31st Jul 20157:00 amRNSTotal Voting Rights
20th Jul 20157:00 amRNSStudy Results
9th Jul 20158:39 amRNSExercise of Options
6th Jul 20152:08 pmRNSIssue of Equity
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20157:00 amRNSFirst server sale of TexRAD in Canada
4th Jun 20159:56 amRNSStmnt re Share Price Movement
3rd Jun 20157:00 amRNSIssue of Equity
15th May 20157:00 amRNSCollaboration with University of Texas
11th May 20153:09 pmRNSPreliminary results from the Oxford Stone Group
29th Apr 20157:00 amRNSDrug Trial and Trading Update
28th Apr 20157:00 amRNSCollaboration with Princess Alexandra Hospital, AU
27th Apr 20157:00 amRNSFirst sale of TexRAD in South Korea
23rd Apr 201512:15 pmRNSStmnt re Share Price Movement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.